Biologics in hidradenitis suppurativa: Progress and new directions

There are currently 2 Food and Drug Administration-approved treatments for hidradenitis suppurativa, and both are biologic medication -- Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha and Secukinumab, an interleukin-17A inhibitor. While both medications have demonstrated mod...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2024-12, Vol.91 (6), p.S27-S30
Main Authors: Charrow, Alexandra, Santiago-Soltero, Karla, Porter, Martina
Format: Article
Language:English
Subjects:
Adalimumab - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Biological Products - therapeutic use
biologics in HS
Female
hidradenitis suppurativa
Hidradenitis Suppurativa - drug therapy
Hidradenitis Suppurativa - immunology
Humans
Interleukin-17 - antagonists & inhibitors
Male
Severity of Illness Index
Treatment Outcome
treatment review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are currently 2 Food and Drug Administration-approved treatments for hidradenitis suppurativa, and both are biologic medication -- Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha and Secukinumab, an interleukin-17A inhibitor. While both medications have demonstrated modest benefit in patients with hidradenitis suppurativa, patients may lose response over time and neither treatment works in all patients. This review outlines the use of these 2 Food and Drug Administration-approved treatments, the best timing of biologic therapy initiation, the evolving pipeline of biologic treatments, and how to best utilize therapeutic drug monitoring to increase the longevity of these critical treatments.
ISSN:0190-9622
1097-6787
1097-6787
DOI:10.1016/j.jaad.2024.09.027